E
Emulate
A privately held company that creates advanced in vitro models for understanding how diseases, medicines, chemicals, and foods affect human health
About Emulate
Emulate Bio is a biotechnology startup that operates in the pharmaceutical and healthcare industry. The company specializes in the development and application of Organ-on-a-Chip technology, a cutting-edge tool that simulates human biology more accurately than traditional animal and spheroid models. This technology is designed to improve the success rate of clinical trials, enhance patient safety, and boost research and development productivity.
Emulate Bio's primary clients are researchers and pharmaceutical companies who are developing new drug therapies. The company provides them with a user-friendly platform that includes instruments, consumables, and software in a flexible, open format. This platform allows researchers to gain a deeper understanding of human biology, which in turn helps them to develop safer and more effective drugs.
The company's business model revolves around selling their Organ-on-a-Chip technology and related products to researchers and pharmaceutical companies. They also generate revenue by publishing research articles, such as their recent publication on integrating Liver-Chip data into drug safety assessments. This publication provides a framework that researchers can use to identify drug-induced liver injury risk, thereby improving the safety and efficiency of drug development workflows.
In summary, Emulate Bio is a promising startup that leverages advanced biotechnology to improve drug development processes, with the ultimate goal of enhancing human health and saving lives.
Source: Dealroom company dataAt a glance
- Status
- Operational
- Founded
- 2014
- Headquarters
- Boston, United States
- Employees
- 73
- Open positions
- 5
- Dealroom signal
- 68.1/100
- Industry
- Health
- Sub-industry
- BioTechnology
- Sector
- Biotech & Life Sciences, Testing, Biotechnology, Microfluidics, Spinout, Biotech and Pharma, medical testing, organ-on-chip, DT and LS, science-based
- Business model
- Manufacturing
- Client focus
- b2b
Knowledge graph
More headlines
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| SERIES FOther financing | Mar 2024 | $47M | $410M | Qiming Venture Partners | — |
| SERIES EOther financing | Sep 2021 | $82M | $328M | Perceptive Advisors · Northpond Ventures | — |
Growth signals
Latest recorded traffic for Emulate is 40K monthly website visits, down 11.1% over the last three months. Emulate's team declined 6.4% over the past year.
Open positions
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Seed1 investor entered at this stage
National Institutes of Health
Series A7 investors entered at this stage
+ND Capital
ATEL Ventures
Techammer
LabCorp
OS Fund- HWHansjörg Wyss
ALS Finding a Cure
Series B and later9 investors entered at this stage
Founders Fund
Starlight Ventures
ALS Investment Fund
SciFi VC
Almanack Investment Partners
Alumni Ventures
Northpond Ventures
Perceptive Advisors
Qiming Venture Partners
Other known investors2 additional known investors
Harvard University
Wyss Institute
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about Emulate on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Emulate’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.







